Blood Borne and Sexual Transmission: Hepatitis B and C

  • Freke ZuureEmail author
  • Susan Hahné
  • Thijs van de Laar
  • Maria Prins
  • Jim van Steenbergen
Part of the Statistics for Biology and Health book series (SBH)


Although the routes of transmission and infectivity differ, the three blood borne infections with most impact on public health are caused by viruses that can cause chronic asymptomatic infections. Human immunodeficiency virus (HIV) is discussed in Chapter 3.


Human Immunodeficiency Virus Sustained Virological Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Alter MJ (2002) Prevention of spread of hepatitis C. Hepatology; 36(5):593–598Google Scholar
  2. Alter MJ (2007) Epidemiology of hepatitis C virus infection. World J Gastroenterol; 13(17):2436–2441Google Scholar
  3. Anzola M, Burgos JJ (2003) Hepatocellular carcinoma: molecular interactions between hepatitis C virus and p53 in hepatocarcinogenesis. Expert Rev Mol Med; 5(28):1–16CrossRefGoogle Scholar
  4. Aweis D, Cooper CD, Brabin B, Beeching N (2001) Serological evidence for Hepatitis B infection in the Somali population of Liverpool. Arch Dis Child; 84 (suppl I):A62Google Scholar
  5. Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR et al. (2001) Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology; 33(6):1479–1487CrossRefGoogle Scholar
  6. Beasley RP, Trepo C, Stevens CE, Szmuness W (1977) The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol; 105(2):94–98Google Scholar
  7. Blackard JT, Sherman KE (2007) Hepatitis C virus coinfection and superinfection. J Infect Dis; 195(4):519–524CrossRefGoogle Scholar
  8. Bonanni P, Pesavento G, Bechini A, Tiscione E, Mannelli F, Benucci C et al. (2003) Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine; 21(7–8):685–691CrossRefGoogle Scholar
  9. Boot HJ, Cremer J, Koedijk F, Ballegooijen M, Op de Coul ELM (2008) Improved tracing of hepatitis B virus transmission chains by phylogenetic analysis based on C region sequences. J Med Virol; 80:233–241Google Scholar
  10. Bowker SL, Smith LJ, Rosychuk RJ, Preiksaitis JK (2004) A review of general hepatitis C virus lookbacks in Canada. Vox Sang; 86(1):21–27CrossRefGoogle Scholar
  11. Busch MP (2001) Closing the window on viral transmission in blood transfusion. In: Stramer SL, ed. Blood safety in the new milennium. American Association of Blood Banks:Betehsda, MD; 33–54Google Scholar
  12. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F et al. (2008)Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology; 135(2):459–467Google Scholar
  13. Chamie G, Bonacini M, Bangsberg DR, Stapleton JT, Hall C, Overton ET et al. (2007) Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis; 44(4):577–583CrossRefGoogle Scholar
  14. Coleman PJ, McQuillan GM, Moyer LA, Lambert SB, Margolis HS (1998) Incidence of hepatitis B virus infection in the United States, 1976–1994: estimates from the National Health and Nutrition Examination Surveys. J Infect Dis; 178(4):954–959CrossRefGoogle Scholar
  15. Courouce AM, Drouet J, Muller JY (1976) Australia antigen subtypes identification. Results. Bibl Haematol; 42:89–127Google Scholar
  16. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M et al. (2007) Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS; 21(8):983–991CrossRefGoogle Scholar
  17. Davis LG, Weber DJ, Lemon SM (1989) Horizontal transmission of hepatitis B virus. Lancet; 1(8643):889–893CrossRefGoogle Scholar
  18. de Oliveira T, Pybus OG, Rambaut A, Salemi M, Cassol S, Ciccozzi M et al. (2006) Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak. Nature; 444(7121):836–837CrossRefGoogle Scholar
  19. Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron AJ (2006) Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol; 44(3):455–461CrossRefGoogle Scholar
  20. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB (2007) Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat; 14(2):107–115CrossRefGoogle Scholar
  21. Dove L, Phung Y, Bzowej N, Kim M, Monto A, Wright TL (2005) Viral evolution of hepatitis C in injection drug users. J Viral Hepat; 12(6):574–583CrossRefGoogle Scholar
  22. Echevarria JM, Avellon A (2006) Hepatitis B virus genetic diversity. J Med Virol; 78 (Suppl 1):S36–S42CrossRefGoogle Scholar
  23. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC (1993) The influence of age on the development of the hepatitis B carrier state. Proc R Soc Lond B Biol Sci; 253(1337):197–201CrossRefGoogle Scholar
  24. European Association for the Study of the Liver (2009) EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol; 50:227–242CrossRefGoogle Scholar
  25. Fisker N, Carlsen NL, Kolmos HJ, Tonning-Sorensen L, Host A, Christensen PB (2006) Identifying a hepatitis B outbreak by molecular surveillance: a case study. BMJ; 332(7537):343–345CrossRefGoogle Scholar
  26. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA et al. (2004) Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int; 65(6):2335–2342Google Scholar
  27. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS et al. (2000) The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet; 355(9207):887–891CrossRefGoogle Scholar
  28. Gale M, Jr., Foy EM (2005) Evasion of intracellular host defence by hepatitis C virus. Nature; 436(7053):939–945CrossRefGoogle Scholar
  29. Gerberding JL (1995) Management of occupational exposures to blood-borne viruses. N Engl J Med; 332(7):444–451CrossRefGoogle Scholar
  30. Giraudon I, Ruf M, Maguire H, Charlett A, Ncube F, Turner J et al. (2007).Increase in newly acquired hepatitis C in HIV positive men who have sex with men across London and Brighton, 2002–2006. Is this an outbreak? Sex Transm Infect 84(2):111–115Google Scholar
  31. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS (2005) A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol; 34(6):1329–1339CrossRefGoogle Scholar
  32. Hahné S, Ramsay M, Balogun K, Edmunds WJ, Mortimer P (2004) Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995–2000: Implications for immunisation policy. J Clin Virol; 29:211–220CrossRefGoogle Scholar
  33. Hahné S, Ramsay M, Soldan K, Balogun K, Mortimer P (2003) Hepatitis B incidence among South Asian children in England and Wales: implications for immunisation policy. Arch Dis Child; 88:1082–1083CrossRefGoogle Scholar
  34. Hauri AM, Armstrong GL, Hutin YJ (2004) The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS; 15(1):7–16CrossRefGoogle Scholar
  35. Herring BL, Page-Shafer K, Tobler LH, Delwart EL (2004) Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis; 190(8):1396–1403CrossRefGoogle Scholar
  36. Hoofnagle JH (2002) Course and outcome of hepatitis C. Hepatology; 36(5):521–529Google Scholar
  37. Hurie MB, Mast EE, Davis JP (1992) Horizontal transmission of hepatitis B virus infection to United States- born children of Hmong refugees. Pediatrics; 89(2):269–273Google Scholar
  38. Hutton DW, Tan D, So SK, Brandeau ML (2007) Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med; 147(7):460–469Google Scholar
  39. Kalinina O, Norder H, Magnius LO (2004) Full-length open reading frame of a recombinant hepatitis C virus strain from St Petersburg: proposed mechanism for its formation. J Gen Virol; 85(7):1853–1857CrossRefGoogle Scholar
  40. Kingsley LA, Rinaldo CR Jr., Lyter DW, Valdiserri RO, Belle SH, Ho M (1990) Sexual transmission efficiency of hepatitis B virus and human immunodeficiency virus among homosexual men. JAMA; 264(2):230–234CrossRefGoogle Scholar
  41. Lanotte P, Dubois F, Le PS, Guerois C, Fimbel B, Bacq Y et al. (1998) The kinetics of antibodies against hepatitis C virus may predict viral clearance in exposed hemophiliacs. J Infect Dis; 178(2):556–559Google Scholar
  42. Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat; 11(2):97–107CrossRefGoogle Scholar
  43. Lok AS (2002) Chronic hepatitis B. N Engl J Med; 346(22):1682–1683CrossRefGoogle Scholar
  44. Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology; 45(2):507–539CrossRefGoogle Scholar
  45. Madhava V, Burgess C, Drucker E (2002) Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis; 2(5):293–302CrossRefGoogle Scholar
  46. Mallette C, Flynn MA, Promrat K (2007) Outcome of screening for hepatitis C virus infection based on risk factors. Am J Gastroenterol 103(1):131–137Google Scholar
  47. Memon MI, Memon MA (2002) Hepatitis C: an epidemiological review. J Viral Hepat; 9(2):84–100CrossRefGoogle Scholar
  48. Medley GF, Lindop NA, Edmunds WJ, Nokes DJ (2001) Hepatitis-B virus endemicity: heterogeneity, catastrophic dynamics and control. Nat Med; 7(5):619–624CrossRefGoogle Scholar
  49. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S et al. (2002) Protection against persistence of hepatitis C. Lancet; 359(9316):1478–1483CrossRefGoogle Scholar
  50. Micallef JM, Kaldor JM, Dore GJ (2006) Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat; 13(1):34–41CrossRefGoogle Scholar
  51. Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I et al. (2007) High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat; 14(6):413–418CrossRefGoogle Scholar
  52. Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S (2007) Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol; 45(4):1102–1112CrossRefGoogle Scholar
  53. National Institutes of Health Consensus Development Conference Statement (2002) Management of hepatitis C: 2002-June 10–12, 2002. Hepatology; 36(5 Suppl 1):S3–20Google Scholar
  54. Ndiaye SM, Hopkins DP, Shefer AM, Hinman AR, Briss PA, Rodewald L et al. (2005) Interventions to improve influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among high-risk adults: a systematic review. Am J Prev Med; 28(5 Suppl):248–279CrossRefGoogle Scholar
  55. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL et al. (2007) Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology; 132(4):1287–1293CrossRefGoogle Scholar
  56. Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK et al. (2004) Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology; 47(6):289–309CrossRefGoogle Scholar
  57. Novick DM, Kreek MJ (2008) Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction; 103(6):905–918CrossRefGoogle Scholar
  58. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M (1991) Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med; 324(24):1699–1704CrossRefGoogle Scholar
  59. Patel K, Muir AJ, McHutchison JG (2006) Diagnosis and treatment of chronic hepatitis C infection. BMJ; 332(7548):1013–1017CrossRefGoogle Scholar
  60. Posthouwer D, Plug I, van der Bom JG, Fischer K, Rosendaal FR, Mauser-Bunschoten EP (2005) Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment. Haemophilia; 11(3):270–275CrossRefGoogle Scholar
  61. Pybus OG, Drummond AJ, Nakano T, Robertson BH, Rambaut A (2003) The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol; 20(3):381–387CrossRefGoogle Scholar
  62. Salisbury D, Ramsay M, Noakes Keds. (2006) Immunisation against infectious disease. HMSO: LondonGoogle Scholar
  63. Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Des Jaklais D, Flom PL et al. (2007) Non-injection drug use and Hepatitis C Virus: a systematic review. Drug and Alcohol Dependence; 89(1):1–12CrossRefGoogle Scholar
  64. Seeff LB (2002) Natural history of chronic hepatitis C. Hepatology; 36(5):S35–S36Google Scholar
  65. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP (2006) Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev; 28:112–125CrossRefGoogle Scholar
  66. Simmonds P (2001) The origin and evolution of hepatitis viruses in humans. J Gen Virol; 82(Pt 4):693–712Google Scholar
  67. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S et al. (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology; 42(4):962–973CrossRefGoogle Scholar
  68. Sutton AJ, Gay NJ, Edmunds WJ (2006b) Modelling the impact of prison vaccination on hepatitis B transmission within the injecting drug user population of England and Wales. Vaccine; 24(13):2377–2386CrossRefGoogle Scholar
  69. Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M (2006a) Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis; 6:93CrossRefGoogle Scholar
  70. Sweeting MJ, de Angelis D, Neal KR, Ramsay ME, Irving WL, Wright M et al. (2006) Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol; 59(2):144–152CrossRefGoogle Scholar
  71. Sypsa V, Hadjipaschali E, Hatzakis A (2001) Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees. Eur J Epidemiol; 17(8):721–728CrossRefGoogle Scholar
  72. Sypsa V, Touloumi G, Papatheodoridis GV, Tassopoulos NC, Ketikoglou I, Vafiadis I et al. (2005) Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J Viral Hepat; 12(5):543–550CrossRefGoogle Scholar
  73. Takeda A, Jones J, Shepherd J, Davidson P, Price A (2007) A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. J Viral Hepat; 14(2):75–88CrossRefGoogle Scholar
  74. Takkenberg B, de Bruijne J, Weegink C, Jansen P, Reesink H (2008) Novel therapies in hepatitis B and C. Curr Gastroenterol Rep; 10(1):81–90CrossRefGoogle Scholar
  75. Tanaka Y, Hanada K, Mizokami M, Yeo AE, Shih JW, Gojobori T et al. (2002) Inaugural Article: A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA; 99(24):15584–15589CrossRefGoogle Scholar
  76. The Global Burden Of Hepatitis C Working Group (2004) Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol; 44(1):20–29CrossRefGoogle Scholar
  77. Thio CL, Seaberg EC, Skolasky R, Jr., Phair J, Visscher B, Munoz A et al. (2002) HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet; 360(9349):1921–1926CrossRefGoogle Scholar
  78. Thompson ND, Perz JF, Moorman AC, Holmberg SD (2009) Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998–2008. Ann Intern Med; 150(1):33–39Google Scholar
  79. Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C et al. (2006) Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat; 13(4):256–263CrossRefGoogle Scholar
  80. van de Laar TJ, Pybus OG, Bruisten SM, Brown D, Nelson M, Bhagani S et al. (2009) Evidence of a large, international HCV transmission network in HIV-positive men who have sex with men. Gastroenterology 136(5):1609–1617Google Scholar
  81. Vandelli C, Renzo F, Romano L, Tisminetzky S, De Palma M, Stroffolini T et al. (2004) Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol; 99(5):855–859CrossRefGoogle Scholar
  82. van den Berg C, Smit C, van Brussel G, Coutinho R, Prins M (2007) Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction; 102(9):1454–1462CrossRefGoogle Scholar
  83. van Houdt R, Bruisten SM, Koedijk FD, Dukers NH, op de Coul EL, Mostert MC et al. (2007) Molecular epidemiology of acute hepatitis B in the Netherlands in 2004: nationwide survey. J Med Virol; 79(7):895–901Google Scholar
  84. van Houdt R, Koedijk FDH, Bruisten SM, op de Coul EL, Heijnen MLA, Waldhober Q, et al. (2009) Hepatitis B vaccination targeted toward behavioral-risk groups in the Netherlands: does it work? Vaccine 27(27):3530–3535Google Scholar
  85. van Steenbergen JE, Niesters HGM, Op de Coul ELM, van Doornum GJJ, Osterhaus ADME, Leentvaar-Kuijpers A et al. (2002) Molecular epidemiology of Hepatitis B Virus in Amsterdam 1992–1997. J Med Virol; 66:159–165Google Scholar
  86. Vickerman P, Hickman M, Judd A (2007) Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. Int J Epidemiol; 36(2):396–405CrossRefGoogle Scholar
  87. Weigand K, Stremmel W, Encke J (2007) Treatment of hepatitis C virus infection. World J Gastroenterol; 13(13):1897–1905Google Scholar
  88. Williams JR, Nokes DJ, Medley GF, Anderson RM (1996). The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect; 116(1):71–89Google Scholar
  89. Wright NM, Tompkins CN (2006) A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users. Harm Reduct J; 3:27CrossRefGoogle Scholar
  90. Xiridou M, Wallinga J, Dukers-Muijers N, Coutinho R (2008) Hepatitis B vaccination and changes in sexual risk behaviour among men who have sex with men in Amsterdam. Epidemiol Infect; 137(4):504–512Google Scholar
  91. Yeung LT, King SM, Roberts EA (2001) Mother-to-infant transmission of hepatitis C virus. Hepatology; 34(2):223–229CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Freke Zuure
    • 1
    Email author
  • Susan Hahné
    • 2
  • Thijs van de Laar
    • 1
  • Maria Prins
    • 1
  • Jim van Steenbergen
    • 3
  1. 1.Cluster Infectious DiseasesPublic Health Service of AmsterdamAmsterdamNetherlands
  2. 2.Center for Infectious Disease Control, RIVMBilthovenNetherlands
  3. 3.Center for Infectious Disease Control, RIVMBilthovenThe Netherlands

Personalised recommendations